Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Simulation-Based Patient Education to Address Radiotherapy-Related Anxiety in Cancer Patients (ARAISE) (ARAISE)

6 agosto 2026 aggiornato da: Prof. Dr. Rami El Shafie, University Medical Center Goettingen

Addressing Radiotherapy Anxiety Through Immersive Simulation and Education: Effects of a Simulation-Based Patient Education Intervention on Psychosocial Burden in Cancer Patients Receiving Radiotherapy (ARAISE)

For the majority of cancer patients, radiotherapy is a crucial component of their treatment process. However, many patients experience anxiety before or during radiotherapy. This anxiety may be related not only to the cancer diagnosis and its prognosis but also to unfamiliar aspects of the treatment process, the equipment, and the treatment environment. General or non-specific feelings of anxiety may also become associated with the radiotherapy setting, even when patients are not able to identify a specific treatment-related concern. Uncertainty about what will happen during treatment sessions can further increase anxiety and may affect patients' overall well-being. The ARAISE project consists of two consecutive parts. In the first part, health care professionals from different disciplines and patient representatives take part in a Delphi consensus process to identify and prioritize the treatment-specific fears of patients receiving radiotherapy. The results of this first part are used to define the content of the education session that is tested in the second part. The second part is a randomized controlled study in patients receiving radiotherapy for cancer. Participants will be assigned by chance, in equal numbers, to one of two groups. All participants will receive the usual patient education provided before radiotherapy. In addition, participants in one group will receive a single immersive, simulation-based education session after the planning CT scan and before the start of treatment. The main question is whether the additional session leads to lower state anxiety at the first radiotherapy fraction compared with usual patient education alone. The study also compares state anxiety at other time points, health-related quality of life, and how well informed participants feel about their treatment. Finally, the study assesses whether the additional education session is feasible, well accepted, and practical to provide as part of routine radiotherapy care.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Descrizione dettagliata

Despite continued medical progress, cancer remains one of the leading causes of death worldwide. A significant number of cancer patients receive radiation therapy at some point during the treatment process, depending on the expected therapeutic benefit. The continued rise in the incidence of malignant diseases highlights the need to refine existing treatment pathways and integrate them into a comprehensive continuum of patient-centered care. A key component of these efforts is the systematic collection and assessment of the needs of patients in a growing and increasingly diverse patient population. In the field of radiation therapy, anxiety and psychological distress are clinically relevant factors that may have a lasting negative impact both on the subjective treatment experience and on treatment compliance, treatment preparation, and treatment quality. A large percentage of radiation therapy patients experience a level of psychological distress that is considered clinically significant and requires treatment. The resulting needs can be categorized into physical, psychological, and social dimensions, and the extent of the observed psychological distress varies significantly among different tumor types but essentially remains stable over the treatment course, with a slight tendency to decrease. Assessments of patient needs often differ among the professional groups participating in the therapy process. The currently standard practice of information counseling conducted by a physician alone is often insufficient to effectively address or alleviate existing treatment-related anxieties. The state-trait anxiety model developed by Charles Spielberger distinguishes between two different forms of anxiety. State anxiety describes a temporary emotional state associated with increased stimulation of the autonomic nervous system, and its intensity can fluctuate. In the context of radiation therapy, potential triggers may include the treatment machine with its specific sounds, the windowless treatment room with its heavy lead-lined door, and the inevitable situation in which the patient is alone during the treatment session. Trait anxiety, on the other hand, is a dispositional factor that represents a stable personality trait and describes the tendency to mistakenly assess objectively low-risk situations as threatening and to react with a disproportionately high level of anxiety. Both dimensions are relevant to the study context, as patients with pronounced trait anxiety generally react more strongly to stress-inducing situations, which in turn can manifest as increased state anxiety. The State-Trait Anxiety Inventory (STAI) is the established tool for the standardized assessment of both dimensions. A validated German-language adaptation (STAI-G) is available. To address these fears, immersive simulation techniques that provide patient-oriented guidance and, as a result, offer more personalized, one-on-one counseling can be valuable in alleviating the anxiety. The ARAISE project addresses these gaps in two consecutive parts. The first study part is a Delphi consensus procedure comprising two to three rounds involving radiation therapists, psycho-oncologists, patient representatives, physicians, and users of the VERT simulation software. In this process, treatment-specific fears of patients undergoing radiation therapy are identified from a multiprofessional perspective and ranked by priority. Its results determine the content of the educational intervention evaluated in the second study part. The subsequent second study part is a prospective, single-center, randomized controlled study with a 1-to-1 allocation ratio and a planned sample size of 144 patients. The participants in the control group receive standard counseling, provided prior to the start of radiation therapy. Participants in the intervention group will receive the same standard counseling, supplemented by a one-time, structured, simulation-based counseling session lasting 15 to 20 minutes, which will be conducted after the planning CT scan and before the first radiation therapy fraction. The session uses the immersive radiation therapy simulation software VERT 9.0 and is led by the principal investigator conducting the study, a medical educator with many years of clinical experience in radiation therapy. Assessments are performed at four time points: T0 (baseline before randomization), T1 (immediately after the planning CT or after the education session), T2 (first radiotherapy fraction), and T3 (fifth radiotherapy fraction). The primary endpoint is state anxiety at T2, measured with the STAI-G Form X1 and adjusted for the baseline value at T0. Secondary endpoints are state anxiety at T1 and T3, HRQoL at T3 (EORTC QLQ-C30), and the perceived amount of information received at T1 (EORTC QLQ-INFO25). Overall, ARAISE aims to develop and evaluate a patient-centered educational approach that may improve patients' preparation for radiotherapy and support the integration of their individual informational and psychological needs into routine care.

Tipo di studio

Interventistico

Iscrizione (Stimato)

144

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Lower Saxony
      • Göttingen, Lower Saxony, Germania, 37075
        • Department of Radiotherapy and Radiation Oncology, University Medical Center Goettingen
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Rami El Shafie, Prof. Dr. med.

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Age 18 years or older
  • Histologically or cytologically confirmed malignant tumor disease
  • Stage I - III (UICC TNM classification)
  • ECOG performance status ≤ 2
  • Curative-intent external beam radiotherapy regimen with at least 5 fractions
  • First course of radiotherapy
  • Able to independently operate the electronic data collection instrument
  • Written informed consent after study information
  • Sufficient German language proficiency to read and complete the study questionnaires independently and without translation assistance

Exclusion Criteria:

  • Lack of capacity to provide informed consent
  • Pregnancy or breastfeeding
  • Stereotactic radiotherapy
  • Emergency treatment indication
  • Acute suicidality, acute psychosis, or other acute psychiatric disorder
  • Initiation of or dose change in psychotropic medication within 4 weeks before baseline (T0)
  • Cognitive impairment that precludes independent completion of the questionnaires
  • Visual or auditory impairment that prevents perception of the on-screen or audio content despite available aids

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: Standard Patient Education
Participants receive standard patient education before radiotherapy according to routine clinical practice. Standard patient education comprises the physician consultation covering the indication and aim of radiotherapy, treatment planning and delivery, possible acute and late side effects, and organizational aspects of care. No simulation-based education session is provided. Prescribed oncological treatment and routine radiotherapy care are not altered.
Sperimentale: Simulation-Based Patient Education
Participants receive standard patient education as in the control arm and, in addition, a single structured simulation-based patient education session after the planning CT and before the first radiotherapy fraction.
A single, standardized, simulation-based patient education session lasting 15 to 20 minutes, conducted in addition to the standard education session that takes place after the planning CT scan and before the first radiation therapy fraction. This session uses the immersive radiation therapy simulation software VERT 9.0 to visualize the treatment room, the linear accelerator, and the treatment process. In addition to illustrating the treatment process, targeted information is provided to address treatment-specific fears identified as priorities in the Delphi consensus. The session is conducted by the principal investigator following a standardized procedure to ensure comparability among participants. The prescribed oncological treatment and routine radiation therapy remain unchanged.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
State anxiety at the first radiotherapy fraction (STAI-G Form X1)
Lasso di tempo: First radiotherapy fraction (T2), approximately 2 weeks after randomization
State anxiety at the first radiotherapy fraction (T2), measured with the state scale (Form X1) of the German version of the State-Trait Anxiety Inventory (STAI-G). The sum score comprises 20 items and ranges from 20 to 80, with higher scores indicating greater state anxiety. The adjusted between-group difference in means at T2 is analyzed by analysis of covariance with the baseline state anxiety score at T0 as a continuous covariate and dichotomized trait anxiety at T0 as a factor. The effect measure is the adjusted mean difference with a 95% confidence interval.
First radiotherapy fraction (T2), approximately 2 weeks after randomization

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
State anxiety after the planning CT or education session (STAI-G Form X1)
Lasso di tempo: T1, immediately after the planning CT or after the education session, approximately 1 week after randomization
State anxiety at T1, measured with the state scale (Form X1) of the German version of the State-Trait Anxiety Inventory (STAI-G). Scores range from 20 to 80, with higher scores indicating greater state anxiety. Analyzed by analysis of covariance with the baseline state anxiety score at T0 as a continuous covariate and dichotomized trait anxiety at T0 as a factor.
T1, immediately after the planning CT or after the education session, approximately 1 week after randomization
State anxiety at the fifth radiotherapy fraction (STAI-G Form X1)
Lasso di tempo: Fifth radiotherapy fraction (T3), approximately 3 weeks after randomization
State anxiety at T3, measured with the state scale (Form X1) of the German version of the State-Trait Anxiety Inventory (STAI-G). Scores range from 20 to 80, with higher scores indicating greater state anxiety. Analyzed by analysis of covariance with the baseline state anxiety score at T0 as a continuous covariate and dichotomized trait anxiety at T0 as a factor.
Fifth radiotherapy fraction (T3), approximately 3 weeks after randomization
Health-related quality of life: Global Health Status/Quality of Life (EORTC QLQ-C30)
Lasso di tempo: Fifth radiotherapy fraction (T3), approximately 3 weeks after randomization
Health-related quality of life at T3, measured with the EORTC QLQ-C30 and linearly transformed to a score from 0 to 100, with higher scores indicating a greater global health status and quality of life. Analyzed by analysis of covariance with group as a factor, the T0 Global Health Status/Quality of Life score as a continuous covariate, and dichotomized trait anxiety at T0 as a factor. Functioning and symptom scales are reported descriptively only.
Fifth radiotherapy fraction (T3), approximately 3 weeks after randomization
Perceived amount of information received: "Information about the treatment" scale (EORTC QLQ-INFO25)
Lasso di tempo: T1, immediately after the planning CT or after the education session, approximately 1 week after randomization
Perceived amount of information received at T1, measured with the multi-item scale "Information about the treatment" (items 38 to 43) of the EORTC QLQ-INFO25 and linearly transformed to a score from 0 to 100, with higher scores indicating a greater perceived amount of information. Groups are compared in a linear model with group as a factor and dichotomized trait anxiety at T0 as the only adjustment variable. The remaining multi-item scales, single items, the total score, and the assessment at T2 are reported descriptively.
T1, immediately after the planning CT or after the education session, approximately 1 week after randomization
Feasibility of the simulation-based patient education intervention
Lasso di tempo: From enrollment to the fifth radiotherapy fraction (T3), approximately 3 weeks per participant
Composite descriptive endpoint with target values defined a priori: recruitment rate of at least 50%, retention rate of at least 80% at T3, protocol adherence of at least 90%, data completeness of at least 85% from T0 to T3, and tolerability defined as discontinuation due to intervention-associated distress reactions in no more than 10% of participants. All rates are reported with two-sided 95% confidence intervals. No formal hypothesis testing is performed.
From enrollment to the fifth radiotherapy fraction (T3), approximately 3 weeks per participant

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Moderation of the intervention effect on state anxiety at T2 by trait anxiety
Lasso di tempo: First radiotherapy fraction (T2), approximately 2 weeks after randomization
Dispositional trait anxiety is measured once at baseline (T0) with the trait scale (Form X2) of the German version of the State-Trait Anxiety Inventory (STAI-G) and dichotomized at a threshold of 40 points or higher. The group-by-trait-anxiety interaction term is tested in the analysis of covariance model of the primary endpoint (state anxiety at T2). Dichotomized trait anxiety additionally serves as a stratification factor for randomization and as a prognostic factor in all analyses of state anxiety. This analysis is not independently powered and is interpreted as hypothesis-generating.
First radiotherapy fraction (T2), approximately 2 weeks after randomization
Effect modification of the primary endpoint by prespecified participant and treatment characteristics
Lasso di tempo: First radiotherapy fraction (T2), approximately 2 weeks after randomization
Effect modification of state anxiety at T2 by irradiation site (central nervous system, head and neck, breast, thorax, abdomen, pelvis), sex, educational level, and concomitant systemic therapy, assessed via the respective interaction terms with treatment allocation in the model of the primary endpoint. These analyses are not independently powered and are interpreted as hypothesis-generating.
First radiotherapy fraction (T2), approximately 2 weeks after randomization

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Collaboratori

Investigatori

  • Investigatore principale: Rami El Shafie, Prof. Dr. med., Department of Radiotherapy and Radiation Oncology, University Medical Center Goettingen (UMCG)
  • Direttore dello studio: Stephan-Peter Landgraff, M.Ed., Faculty of Health Sciences, Medical School Berlin (MSB)

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 gennaio 2028

Completamento primario (Stimato)

1 maggio 2030

Completamento dello studio (Stimato)

1 dicembre 2030

Date di iscrizione allo studio

Primo inviato

17 luglio 2026

Primo inviato che soddisfa i criteri di controllo qualità

17 luglio 2026

Primo Inserito (Effettivo)

23 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

11 agosto 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 agosto 2026

Ultimo verificato

1 agosto 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • ARAISE-RT-UMG-2026

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data will not be shared with external researchers. Study data contain sensitive health information and will be stored and analyzed in pseudonymized form on secure institutional servers in accordance with the study protocol and applicable data-protection requirements.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi